|
注册号: Registration number: |
ChiCTR2400088952 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-29 14:44:36 |
|
注册时间: Date of Registration: |
2024-08-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
24h内急性大中血管闭塞性极大核心梗死卒中患者血管内治疗的多中心、前瞻性队列研究 |
|
Public title: |
Extreme Large Core Infarct Stroke within 24 Hour Time Window: A Multi-center, Prospective, Chinese Cohort of Endovascular Thrombectomy in Acute Stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
24h内急性大中血管闭塞性极大核心梗死卒中患者血管内治疗的多中心、前瞻性队列研究(ELCIS-24研究) |
|
Scientific title: |
Extreme Large Core Infarct Stroke within 24 Hour Time Window: A Multi-center, Prospective, Chinese Cohort of Endovascular Thrombectomy in Acute Stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
马金福 |
研究负责人: |
资文杰 |
|
Applicant: |
Ma Jinfu |
Study leader: |
Zi Wenjie |
|
申请注册联系人电话: Applicant telephone: |
+86 152 8447 8486 |
研究负责人电话:
Study leader's |
+86 185 2303 3816 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Jin_fu_Ma@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ziwenjie1981@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
|
Applicant address: |
183 Xinqiao Main Street, Shapingba District, Chongqing |
Study leader's address: |
183 Xinqiao Main Street, Shapingba District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
陆军军医大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of the Army Medical University |
||
|
研究负责人所在单位: |
陆军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of the Army Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-研第041-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Second Affiliated Hospital of Army Medical University, PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-27 00:00:00 | ||
|
伦理委员会联系人: |
胡岚岚 |
||
|
Contact Name of the ethic committee: |
Hu Lanlan |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区新桥正街183号 |
||
|
Contact Address of the ethic committee: |
183 Xinqiao Main Street, Shapingba District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6877 5422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
陆军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of the Army Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街183号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
183 Xinqiao Main Street, Shapingba District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
陆军军医大学第二附属医院人才建设专项项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Special Talent Development Project of the Second Affiliated Hospital of Army Medical University |
||||||||||||||||||||||
|
研究疾病: |
急性缺血性卒中 |
||||||||||||||||||||||
|
Target disease: |
Acute ischemic stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探讨24h内极大核心梗死性卒中患者血管内治疗的有效性和安全性 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the efficacy and safety of endovascular treatment for large vessel occlusion in patients with extrem large core infarct stroke within the 24-hour time window. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1) 经头颅计算机断层扫描(CT)或核磁共振成像(MRI)证实颅内出血; 2) 发病前mRS评分≥2分; 3) 妊娠或哺乳期妇女; 4) 遗传学或获得性出血体质,抗凝因子缺乏;或已使用抗凝药且INR>3; 5) 影像学上具有占位效应的颅内肿瘤(微小脑膜瘤除外); 6) 任何疾病晚期致预期寿命<6个月; 7) 预期不能完成随访; 8) 脑疝导致颅脑中线移位; 9) 含有严重并发症可能影响患者预后和随访(癌症、严重心衰、肾衰); 10) 怀疑脓毒性栓塞或细菌性心内膜炎。 11) 正在参与其他临床实验; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Confirmed intracranial hemorrhage through computed tomography (CT) or magnetic resonance imaging (MRI); 2.Pre-stroke modified Rankin Scale (mRS) score >= 2; 3.Pregnancy or breastfeeding women; 4.Genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or use of anticoagulant medication with an International Normalized Ratio (INR) > 3; 5.Presence of intracranial tumors with mass effect on imaging (excluding small meningiomas); 6.Any end-stage disease with expected survival less than 6 months; 7.Anticipated inability to complete follow-up; 8.Brain herniation causing midline shift; 9.Presence of severe complications that may affect patient prognosis and follow-up (cancer, severe heart failure, renal failure); 10. Suspected septic embolism or bacterial endocarditis; 11. Participating in other clinical trials; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-11-01 00:00:00至 To 2026-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
相关论文发表5年后在Resman平台公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Related papers published five years later, the IPD will be shared on ResMan. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例报告表(CRF) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use Case Record Form (CRF) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |